John H. Leaman, M.D. has served as the Chief Financial Officer at Cellarity since March 2023 and during his tenure has helped to oversee the close of the company’s partnership deal with Novo Nordsk, lead the effort to close the Company’s Series D financing, and prepared the Company’s finance team for a planned IPO.

From June 2019 to February 2023 Dr. Leaman served as the Chief Financial Officer and Chief Business Officer at Impel Pharmaceuticals where helped lead the Company’s IPO in April 2021. From October 2017 to March 2019, Dr. Leaman served as the Chief Financial Officer and Head of Corporate Development at Selecta Biosciences Inc. From June 2016 to September 2017, he served as Head of Corporate Development at InfaCare Pharmaceutical Corp., a specialty pharmaceutical company, until it was acquired by Mallinckrodt plc. in September 2017. From August 2014 to March 2016, Dr. Leaman was the Chief Financial Officer of Medgenics Inc.

He also previously held senior roles at Shire plc. and Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies, and began his career serving a range of life sciences companies as an Associate Principal at McKinsey & Company.

He received an M.D. from the Perelman School of Medicine at the University of Pennsylvania, an M.B.A. from the Wharton School at the University of Pennsylvania, a B.A. in psychology, philosophy and physiology from Oriel College, University of Oxford while completing a Rhodes Scholarship, and a B.S. in biology from Elizabethtown College.